Actively Recruiting
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
Led by M.D. Anderson Cancer Center · Updated on 2026-02-06
120
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.
CONDITIONS
Official Title
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older with colorectal liver metastases undergoing elective liver surgery with curative intent
- Primary colorectal cancer previously removed or planned for removal at time of liver surgery
- Received at least 4 cycles of preoperative chemotherapy (e.g., FOLFOX, FOLFIRI, with or without bevacizumab or panitumumab/cetuximab) between 07/01/2021 and 12/31/2023
You will not qualify if you...
- Presence of primary colorectal tumor remaining untreated in the body
- Unable or not planned to receive postoperative chemotherapy
- Unwilling or unable to undergo blood draws for ctDNA testing
- Having other active cancers requiring treatment
- Women who are pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
T
Timothy Newhook
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here